Immunogenicity of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients With Morquio A Syndrome: Results From MOR-004, a Phase III Trial

ATS Statement: Guidelines for the Six-Minute Walk Test

American Journal of Respiratory and Critical Care Medicine · 2002 · 10.8K citations

Medicine, Kinesiology, Physical Medicine +13

Second symposium on the definition and management of anaphylaxis: Summary report—Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium

Hugh A. Sampson, Anne Muñoz‐Furlong, Ronna L. Campbell et al. · Journal of Allergy and Clinical Immunology · 2006 · 2.3K citations

Life Sciences, Immunology, Internal Medicine +16

The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: Lessons learned from infantile Pompe disease

Suhrad G. Banugaria, Sean N. Prater, Yiu-Ki Ng et al. · Genetics in Medicine · 2011 · 251 citations · Full text

Pharmacy, Immunology, Pediatrics +15

Incidence of the mucopolysaccharidoses in Northern Ireland

John W. Nelson · Human Genetics · 1997 · 226 citations

Veterinary Medicine, Pathology, Spatial Epidemiology +1

Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo‐controlled study

Christian J. Hendriksz, Barbara K. Burton, Thomas R. Fleming et al. · Journal of Inherited Metabolic Disease · 2014 · 211 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +12